COMMUNIQUÉS West-GlobeNewswire

Nacuity Pharmaceuticals Granted U.S. FDA Breakthrough Therapy Designation for NPI-001 (N-acetylcysteine amide) Tablets for the Treatment of Retinitis Pigmentosa
02/10/2025
FORT WORTH, Texas, Oct. 02, 2025 (GLOBE NEWSWIRE) -- Nacuity Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing treatments for retinitis pigmentosa, cataracts and other diseases caused by [...]
Ultrack Systems Inc. (OTC: MJLB) Subsidiary Better Pets Launches First Health Canada–Approved Product, Kicking Off Rebranded Pet Wellness Line
02/10/2025
TORONTO, Oct. 02, 2025 (GLOBE NEWSWIRE) -- Ultrack Systems Inc. (OTC: MJLB) (“Ultrack” or the “Company”), through its wholly owned subsidiary Better Pets, is pleased to announce the upcoming launch of the Better Pets [...]
Incendia Therapeutics Presents Two Posters on its Lead Asset PRTH-101 in Thymic Cancers at the 15th International Thymic Malignancy Interest Group (ITMIG) Annual Meeting
02/10/2025
Initial Phase 1 data suggest PRTH-101 contributes to disease control in recurrent/metastatic thymic epithelial carcinoma (TEC) with median progression-free survival (mPFS) of 7.9 months and 1 partial response (PR) [...]
Cannara annonce le règlement proposé de débentures convertibles par le biais d’une émission d’actions
02/10/2025
MONTRÉAL, 02 oct. 2025 (GLOBE NEWSWIRE) -- Cannara Biotech Inc. (« Cannara », « la Société », « nous » ou « notre ») ( TSXV : LOVE ) ( OTCQB : LOVFF ) ( FRA : 8CB0) , producteur verticalement intégré de cannabis de [...]
Cannara Announces Proposed Settlement of Convertible Debenture via Share Issuance
02/10/2025
MONTREAL, Oct. 02, 2025 (GLOBE NEWSWIRE) -- Cannara Biotech Inc. (“ Cannara ”, “the Company ”, “ us ” or “ we ”) ( TSXV: LOVE ) ( OTCQB: LOVFF ) ( FRA: 8CB0 ), a vertically integrated producer of premium-grade cannabis [...]
PharmAla Completes Shipment of LaNeo™ MDMA to Johns Hopkins
02/10/2025
TORONTO, Oct. 02, 2025 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (“ PharmAla ” or the “ Company ”) (CSE: MDMA) (OTCQB:MDXXF), a biotechnology company focused on the research, development, and manufacturing of [...]
Positron Corporation Enters Industry Partnership Agreement with MedAxiom
02/10/2025
Buffalo, NY, Oct. 02, 2025 (GLOBE NEWSWIRE) -- Positron Corporation (“Positron” or the “Company”) (OTC: POSC), a leading molecular imaging technology company specializing in PET and PET-CT imaging systems and clinical [...]
24/7 Market News: Kraig Labs Unlocks Spider Silk at Scale, Solving a Historical Problem for Nature’s Toughest Fiber
02/10/2025
DENVER, Oct. 02, 2025 (GLOBE NEWSWIRE) -- 247marketnews.com , a pioneer in digital media dedicated to the swift distribution of financial market news and information, reports that Kraig Biocraft Laboratories (OTCQB: [...]
Precision Neuroscience Reports First High-Bandwidth Brain–Computer Interface Achieved Without Open Surgery
02/10/2025
Study in Nature Biomedical Engineering details Precision’s surface-based system and shows results from the first five patients NEW YORK, Oct. 02, 2025 (GLOBE NEWSWIRE) -- Precision Neuroscience Corporation (Precision), [...]
AM-Pharma Completes Enrollment in Phase 2 Study of Ilofotase Alfa for Prevention of Cardiac Surgery-Associated Renal Damage
02/10/2025
Utrecht, The Netherlands, October 2, 2025 – AM-Pharma B.V. today announced that it has successfully completed enrollment of patients in its ongoing Phase 2 clinical trial evaluating ilofotase alfa for the prevention of [...]
Greenwich LifeSciences Announces Expansion of Flamingo-01 Clinical Trial to Belgium
02/10/2025
STAFFORD, Texas, Oct. 02, 2025 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is [...]
Pennant Completes Purchase of Tennessee, Georgia and Alabama Operations from UnitedHealth Group and Amedisys
02/10/2025
EAGLE, Idaho, Oct. 02, 2025 (GLOBE NEWSWIRE) -- The Pennant Group, Inc. (NASDAQ: PNTG), the parent company of the Pennant group of affiliated home health, hospice, home care and senior living companies, announced today [...]
Immuron Letter to Shareholders – Projects Update
02/10/2025
Highlights: US Tariffs: Immuron does not anticipate any material impact from the recently announced US tariffs on pharmaceutical products Travelan ® Clinical Study: Topline results from the Travelan ® clinical study [...]
Bimergen Energy Secures $50 Million for Battery Energy Storage Project Development
02/10/2025
Newport Beach, CA, Oct. 02, 2025 (GLOBE NEWSWIRE) -- Bimergen Energy Corporation [ OTCQB: BESS ], (“the Company” or “Bimergen”), a developer of utility-scale battery energy storage solutions and an independent power [...]
e-therapeutics relance son activité sous le nom de Tangram Therapeutics et présente LLibra OS
02/10/2025
Ce renouveau marque une étape décisive dans la croissance de la Société, qui prévoit de soumettre sa première demande d’essai clinique (ou CTA, de l’anglais « Clinical Trial Application ») au quatrième trimestre 2025. [...]
Nicox annonce que NCX 470 a démontré une efficacité soutenue jusqu’à 12 mois dans l’essai clinique Denali, sans effets indésirables nouveaux observés
02/10/2025
Communiqué de presse Nicox annonce que NCX 470 a démontré une efficacité soutenue jusqu’à 12 mois dans l’essai clinique Denali, sans effets indésirables nouveaux observés Les analyses additionnelles préplanifiées de l’ [...]
Nicox’s NCX 470 Demonstrates Sustained Efficacy through 12 Months in Denali Clinical Trial with no new Safety Observations
02/10/2025
Press Release Nicox’s NCX 470 Demonstrates Sustained Efficacy through 12 Months in Denali Clinical Trial with no new Safety Observations Additional pre-planned analysis of the NCX 470 Denali trial completed NCX 470 [...]
Igyxos Biotherapeutics Awarded EUR 5.7 Million from the French Government to Accelerate Development of its First-in-class Monoclonal Antibody for the Treatment of Infertility
02/10/2025
TOURS, France, Oct. 02, 2025 (GLOBE NEWSWIRE) -- Igyxos Biotherapeutics, a biotechnology company dedicated to developing innovative monoclonal antibodies for infertility treatment, today announced that it has secured a [...]
New Imprivata Report Finds that Australian Hospitals Save More Than $1.2 Million AUD Annually with Shared-Use Mobile Devices, but Strategic Gaps Still Pose Security and Operational Risk
02/10/2025
The 2025 Imprivata State of Shared Mobile Devices in Healthcare Report identifies the benefits as well as the challenges Australian healthcare organisations face when implementing shared-use mobile devices for clinical [...]

Pages